Atezolizumab Immunotherapy Is Withdrawn From FDA-Approval Process
Understand more about the change in approval for Atezolizumab (Tecentriq®) for TNBC.
PAST ARTICLES
2021
- Adoptive Cell Therapies for Metastatic Solid Cancers
- Oral SERDs for Estrogen Receptor-Positive MBC
- Y-90 Internal Radiation Therapy for Liver Mets
- Update on Hormone Receptor-Positive MBC
- 2021 Update on Metastatic Triple Negative Breast Cancer Treatment
- Treating Breast Cancer Brain Mets
- Lines of Therapy: New Drugs May Change MBC Treatment
2020
- When to Use Surgery & Radiation to the Breast
- HER2-Low Expressing: A New Subcategory of HER2-Negative Breast Cancer?
- Imaging Tests for People with Stage IV Breast Cancer
- PD-L1 Biomarker for Immunotherapy
- What is ER-Low Breast Cancer?
- HER2 Positive Metastatic Breast Cancer Research Update
- Recent FDA Approvals for Metastatic Breast Cancer
- The Tumor Microenvironment
- What is Your Tumor’s Mutation Burden?
- Triple-Negative Breast Cancer Update
2019
- Tips for Reading Cancer News
- What is a Tumor Agnostic Therapy?
- Treating Brain Metastases
- New FDA Approval: A PI3K Inhibitor
- Best of MBC Research News (2018-2019)
- What is Oligometastatic Breast Cancer?
- Getting to the Target: Antibody Drug Conjugates
- First Immunotherapy Approved for MBC
- Liquid Biopsies: More than a Blood Test?
- Get the Latest News on PARP Inhibitors
- New Research Presented at San Antonio
SEARCH OUR SITE
for past articles or specific information.